Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 257,855
  • Shares Outstanding, K 34,153
  • Annual Sales, $ 47,540 K
  • Annual Income, $ -440 K
  • EBIT $ -5 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.75
  • Price/Sales 5.38
  • Price/Cash Flow 230.37
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 634.91% (+12.35%)
  • Historical Volatility 52.12%
  • IV Percentile 94%
  • IV Rank 94.40%
  • IV High 669.42% on 12/08/25
  • IV Low 53.33% on 05/20/25
  • Expected Move (DTE 6) 0.43 (5.63%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 107
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,489
  • Open Int (30-Day) 1,264
  • Expected Range 7.13 to 7.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.00
  • Low Estimate -0.01
  • Prior Year -0.06
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.35 +2.72%
on 12/10/25
9.00 -16.11%
on 11/17/25
-0.23 (-2.96%)
since 11/12/25
3-Month
7.35 +2.72%
on 12/10/25
9.92 -23.89%
on 10/06/25
-1.21 (-13.81%)
since 09/12/25
52-Week
4.68 +61.32%
on 04/09/25
9.92 -23.89%
on 10/06/25
+1.44 (+23.57%)
since 12/12/24

Most Recent Stories

More News
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~  ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01)...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 7.82
2nd Resistance Point 7.72
1st Resistance Point 7.64
Last Price 7.55
1st Support Level 7.46
2nd Support Level 7.36
3rd Support Level 7.28

See More

52-Week High 9.92
Fibonacci 61.8% 7.92
Last Price 7.55
Fibonacci 50% 7.30
Fibonacci 38.2% 6.68
52-Week Low 4.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar